Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Brown

Showing results (241-250 of 259) with videos related to

Pageof 26
Sort By:
Ophthalmology|September 22, 2016
Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID StudiesJeffrey S Heier, Jean-François Korobelnik, David M Brown, et al.
Nature Communications|March 8, 2022
Tree-rings reveal two strong solar proton events in 7176 and 5259 BCENicolas Brehm, Marcus Christl, Timothy D J Knowles, et al.
Ophthalmology|October 3, 2013
Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studiesUrsula Schmidt-Erfurth, Peter K Kaiser, Jean-François Korobelnik, et al.
Therapeutic Advances in Ophthalmology|July 6, 2026
Plain language summary of publication of the 96-week results from the PHOTON study: intravitreal aflibercept 8 mg for diabetic macular edemaDiana V Do, Charles C Wykoff, Sobha Sivaprasad, et al.
Ophthalmology|September 3, 2019
Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 TrialDavid S Liao, Federico V Grossi, Delphine El Mehdi, et al.
Ophthalmology|July 23, 2015
Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID StudiesDavid M Brown, Ursula Schmidt-Erfurth, Diana V Do, et al.
Lancet (London, England)|March 10, 2024
Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trialDavid M Brown, David S Boyer, Diana V Do, et al.
Ophthalmology|November 12, 2025
Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: Ninety-Six-Week Results from the Randomized Phase 2/3 PHOTON TrialDiana V Do, Charles C Wykoff, Sobha Sivaprasad, et al.
Ophthalmology|July 12, 2014
Intravitreal aflibercept for diabetic macular edemaJean-François Korobelnik, Diana V Do, Ursula Schmidt-Erfurth, et al.
JAMA Ophthalmology|July 25, 2024
Severe Spaceflight-Associated Neuro-Ocular Syndrome in an Astronaut With 2 Predisposing FactorsTyson J Brunstetter, Sara R Zwart, Keith Brandt, et al.
Pageof 26

Showing results (241-250 of 259) with videos related to

Sort By:
Pageof 26
Ophthalmology|September 22, 2016
Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID StudiesJeffrey S Heier, Jean-François Korobelnik, David M Brown, et al.
Nature Communications|March 8, 2022
Tree-rings reveal two strong solar proton events in 7176 and 5259 BCENicolas Brehm, Marcus Christl, Timothy D J Knowles, et al.
Ophthalmology|October 3, 2013
Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studiesUrsula Schmidt-Erfurth, Peter K Kaiser, Jean-François Korobelnik, et al.
Therapeutic Advances in Ophthalmology|July 6, 2026
Plain language summary of publication of the 96-week results from the PHOTON study: intravitreal aflibercept 8 mg for diabetic macular edemaDiana V Do, Charles C Wykoff, Sobha Sivaprasad, et al.
Ophthalmology|September 3, 2019
Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 TrialDavid S Liao, Federico V Grossi, Delphine El Mehdi, et al.
Ophthalmology|July 23, 2015
Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID StudiesDavid M Brown, Ursula Schmidt-Erfurth, Diana V Do, et al.
Lancet (London, England)|March 10, 2024
Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trialDavid M Brown, David S Boyer, Diana V Do, et al.
Ophthalmology|November 12, 2025
Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: Ninety-Six-Week Results from the Randomized Phase 2/3 PHOTON TrialDiana V Do, Charles C Wykoff, Sobha Sivaprasad, et al.
Ophthalmology|July 12, 2014
Intravitreal aflibercept for diabetic macular edemaJean-François Korobelnik, Diana V Do, Ursula Schmidt-Erfurth, et al.
JAMA Ophthalmology|July 25, 2024
Severe Spaceflight-Associated Neuro-Ocular Syndrome in an Astronaut With 2 Predisposing FactorsTyson J Brunstetter, Sara R Zwart, Keith Brandt, et al.
Pageof 26